Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jun 2;83(1):74–82. doi: 10.1054/bjoc.2000.1136

Anti-tumour effects and pharmacokinetic profile of 17-(5′ -isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis

I P Nnane 1, B J Long 1, Y-Z Ling 2, D N Grigoryev 1, A M Brodie 1
PMCID: PMC2374539  PMID: 10883671

Abstract

17-(5′-Isoxazolyl)androsta-4,16-dien-3-one (L-39), a novel androstene derivative, was synthesized and evaluated in vitro and in vivo. L-39 showed potent and non-competitive inhibition of human testicular microsomal 17α-hydroxylase/C 17,20-lyase with an IC 50 value of 59 n M and Ki of 22 n M. L-39 also showed potent and competitive inhibition of 5α-reductase in human prostatic microsomes with IC 50 and Ki values of 33 and 28 n M respectively. L-39 (5 μM) has also been shown to manifest anti-androgenic activity in cultures of human prostate cancer cell lines (LNCaP) by preventing the labelled synthetic androgen R1881 (5 n M) from binding to the androgen receptors. Androgen-ependent human próstate cancer xenografts (PC-82) were grown in nude mice and the effects of L-39 (50 mg kg–1day–1) on tumour growth and prostate-specific antigen (PSA) levels were determined after 28 days. L-39 significantly (P< 0.01) diminished tumour growth and wet weights to a similar extent as castration or flutamide treatment. L-39 also significantly (P< 0.01) reduced serum PSA levels by more than 80% in the mice bearing human prostate cancer xenografts. Pharmacokinetic studies were also conducted in male Balb/c mice. After subcutaneous administration of a single bolus dose, L-39 was rapidly absorbed into the systemic circulation. Peak plasma levels occurred at 0.75 h and then declined with a t1/2 of 1.51 h. The bioavailability of L-39 after subcutaneous administration was 28.5%. These results demonstrate that L-39 is a potent inhibitor of androgen synthesis and is effective in reducing the growth of human prostate cancer xenografts in nude mice. Although improvements in the bioavailability are necessary, L-39 is a potential lead compound with this profile as an inhibitor of prostate cancer growth. © 2000 Cancer Research Campaign

Keywords: 17α-hydroxylase/C 17,20-lyase; 5α-reductase; androgens; prostate cancer; pharmacokinetics

Full Text

The Full Text of this article is available as a PDF (117.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angelastro M. R., Laughlin M. E., Schatzman G. L., Bey P., Blohm T. R. 17 beta-(cyclopropylamino)-androst-5-en-3 beta-ol, a selective mechanism-based inhibitor of cytochrome P450(17 alpha) (steroid 17 alpha-hydroxylase/C17-20 lyase). Biochem Biophys Res Commun. 1989 Aug 15;162(3):1571–1577. doi: 10.1016/0006-291x(89)90854-1. [DOI] [PubMed] [Google Scholar]
  2. Ayub M., Levell M. J. Inhibition of testicular 17 alpha-hydroxylase and 17,20-lyase but not 3 beta-hydroxysteroid dehydrogenase-isomerase or 17 beta-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs. J Steroid Biochem. 1987 Nov;28(5):521–531. doi: 10.1016/0022-4731(87)90511-5. [DOI] [PubMed] [Google Scholar]
  3. Bruchovsky N., Wilson J. D. The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem. 1968 Apr 25;243(8):2012–2021. [PubMed] [Google Scholar]
  4. Crawford E. D., Eisenberger M. A., McLeod D. G., Spaulding J. T., Benson R., Dorr F. A., Blumenstein B. A., Davis M. A., Goodman P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419–424. doi: 10.1056/NEJM198908173210702. [DOI] [PubMed] [Google Scholar]
  5. Cunningham G. R., Hirshkowitz M. Inhibition of steroid 5 alpha-reductase with finasteride: sleep-related erections, potency, and libido in healthy men. J Clin Endocrinol Metab. 1995 Jun;80(6):1934–1940. doi: 10.1210/jcem.80.6.7775644. [DOI] [PubMed] [Google Scholar]
  6. Dijkman G. A., Debruyne F. M. Epidemiology of prostate cancer. Eur Urol. 1996;30(3):281–295. doi: 10.1159/000474185. [DOI] [PubMed] [Google Scholar]
  7. Grigoryev D. N., Long B. J., Nnane I. P., Njar V. C., Liu Y., Brodie A. M. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br J Cancer. 1999 Oct;81(4):622–630. doi: 10.1038/sj.bjc.6690739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Klus G. T., Nakamura J., Li J. S., Ling Y. Z., Son C., Kemppainen J. A., Wilson E. M., Brodie A. M. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Cancer Res. 1996 Nov 1;56(21):4956–4964. [PubMed] [Google Scholar]
  9. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  10. Labrie F., Dupont A., Belanger A., Lacoursiere Y., Raynaud J. P., Husson J. M., Gareau J., Fazekas A. T., Sandow J., Monfette G. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983;4(6):579–594. doi: 10.1002/pros.2990040605. [DOI] [PubMed] [Google Scholar]
  11. Li J. S., Li Y., Son C., Brodie A. M. Synthesis and evaluation of pregnane derivatives as inhibitors of human testicular 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 1996 Oct 11;39(21):4335–4339. doi: 10.1021/jm960245f. [DOI] [PubMed] [Google Scholar]
  12. Li J., Li Y., Son C., Banks P., Brodie A. 4-pregnene-3-one-20 beta-carboxaldehyde: a potent inhibitor of 17 alpha-hydroxylase/C17,20-lyase and of 5 alpha-reductase. J Steroid Biochem Mol Biol. 1992 May;42(3-4):313–320. doi: 10.1016/0960-0760(92)90134-5. [DOI] [PubMed] [Google Scholar]
  13. Li J., Li Y., Son C., Brodie A. M. Inhibition of androgen synthesis by 22-hydroximino-23,24-bisnor-4-cholen-3-one. Prostate. 1995 Mar;26(3):140–150. doi: 10.1002/pros.2990260306. [DOI] [PubMed] [Google Scholar]
  14. Ling Y. Z., Li J. S., Liu Y., Kato K., Klus G. T., Brodie A. 17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P450(17 alpha). J Med Chem. 1997 Sep 26;40(20):3297–3304. doi: 10.1021/jm970337k. [DOI] [PubMed] [Google Scholar]
  15. McCague R., Rowlands M. G., Barrie S. E., Houghton J. Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid. J Med Chem. 1990 Nov;33(11):3050–3055. doi: 10.1021/jm00173a022. [DOI] [PubMed] [Google Scholar]
  16. Nakajin S., Takahashi K., Shinoda M. Inhibitory effect and interaction of stanozolol with pig testicular cytochrome P-450 (17 alpha-hydroxylase/C17,20-lyase). Chem Pharm Bull (Tokyo) 1989 Jul;37(7):1855–1858. doi: 10.1248/cpb.37.1855. [DOI] [PubMed] [Google Scholar]
  17. Njar V. C., Brodie A. M. Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer. Curr Pharm Des. 1999 Mar;5(3):163–180. [PubMed] [Google Scholar]
  18. Njar V. C., Kato K., Nnane I. P., Grigoryev D. N., Long B. J., Brodie A. M. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer. J Med Chem. 1998 Mar 12;41(6):902–912. doi: 10.1021/jm970568r. [DOI] [PubMed] [Google Scholar]
  19. Nnane I. P., Kato K., Liu Y., Long B. J., Lu Q., Wang X., Ling Y. Z., Brodie A. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds. Endocrinology. 1999 Jun;140(6):2891–2897. doi: 10.1210/endo.140.6.6832. [DOI] [PubMed] [Google Scholar]
  20. Nnane I. P., Kato K., Liu Y., Lu Q., Wang X., Ling Y. Z., Brodie A. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer. Cancer Res. 1998 Sep 1;58(17):3826–3832. [PubMed] [Google Scholar]
  21. Peters D. H., Sorkin E. M. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia. Drugs. 1993 Jul;46(1):177–208. doi: 10.2165/00003495-199346010-00010. [DOI] [PubMed] [Google Scholar]
  22. Roach M., 3rd The role of PSA in the radiotherapy of prostate cancer. Oncology (Williston Park) 1996 Aug;10(8):1143–1161. [PubMed] [Google Scholar]
  23. Rosenberg A. G., von Eschenbach A. C. Hormonal therapy for prostate cancer. Semin Surg Oncol. 1990;6(2):71–76. doi: 10.1002/ssu.2980060204. [DOI] [PubMed] [Google Scholar]
  24. SAUNDERS F. J. SOME ASPECTS OF RELATION OF STRUCTURE OF STEROIDS TO THEIR PROSTATE--STIMULATING EFFECTS. Natl Cancer Inst Monogr. 1963 Oct;12:139–159. [PubMed] [Google Scholar]
  25. Small E. J., Baron A. D., Fippin L., Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997 Apr;157(4):1204–1207. [PubMed] [Google Scholar]
  26. Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. J Urol. 1984 Jul;132(1):61–63. doi: 10.1016/s0022-5347(17)49464-x. [DOI] [PubMed] [Google Scholar]
  27. Wilson J. D. Role of dihydrotestosterone in androgen action. Prostate Suppl. 1996;6:88–92. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES